GlassScriptPhysician profile
Sumayya Ahmed
NPI 1467450346
$3,750.27
in general payments reported to CMS, 2019-2025
21 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $519 · 2021: $378 · 2022: $634 · 2023: $752 · 2024: $548 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $965.67 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.63 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Abbvie INC. | $401.53 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $348.85 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $318.11 | 2019-2024 | |
| Lilly USA, LLC | $302.03 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Corcept Therapeutics | $167.93 | 2025 | Korlym |
| Exact Sciences Corporation | $111.11 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $109.08 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $94.20 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $56.37 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.57 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.15 | 2022-2023 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.67 | 2025 | Caplyta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.46 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $28.94 | 2023-2024 | Gvoke Hypopen |
| Allergan, INC. | $27.88 | 2020 | |
| Novo Nordisk INC | $26.30 | 2021 | |
| Melinta Therapeutics, LLC | $22.89 | 2022 | |
| Eisai INC. | $14.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumayya Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.